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In the diseases caused by intracellular parasites, among which
one may in general include the virus and rickettsial diseases, the
passive transfer of immune bodies for treatment of the exposed
susceptible has received scant attention in comparison with other
studies related to these diseases and their agents. Such a paucity
of studies has resulted, to some extent, from the widely accepted
premise that signs and symptoms of these groups of diseases in gen-
eral appear only after the intracellular causative agent has become
established in the parasitized cell, relatively safe from the action
of circulating antibodies. In such diseases treatment, even in the
earlier stages, has often been regarded as merely closing the barn
door after the horse has been stolen. The present discussion sug-
gests that such a premise may not be correct in certain virus diseases
and that in the light of such findings as are here recorded, further
study is required of the value of the passive transfer of antibodies
in the diseases caused by intracellular parasites. It is also sug-
gested, in view of these data, that the development of earlier diag-
nostic criteria ofdisease is essential for the lengthening of the period
in which parenterally injected antibodies may be considered as treat-
ment; and further, the suggestion is made that the use of immune
bodies at any time following exposure of the susceptible individual
* These investigations were aided in part by the Commigsion on Measles and
Mumps, Board for the Investigation and Control of Influenza and other Epidemic
Diseases in the Army, Preventive Medicine Service, Office of The Surgeon General,
U. S. Army. Immune globulins were prepared by methods developed in the Depart-
ment of Physical Chemistry, Harvard Medical School, under a contract with the
Office of Scientific Research and Development recommended by the Committee on
Medical Research, from blood collected by the American Red Cross.YALE JOURNAL OF BIOLOGY AND MEDICINE
and during the incubation of the disease should be considered as
treatment.*
The use of human immune bodies in measles
Although the passive transfer of human immune bodies to the
exposed susceptible in measles has received intensive study, until
recently the lack of large quantities of convalescent serum and of
concentrated preparations of immune bodies has prevented studies of
the use of such amounts of immune bodies following the onset of
fever.4' 6 Also, up to the present time conclusive evidence of the
presence of measles cannot be obtained until the Koplik spots have
appeared, although fever, cough, coryza, and conjunctivitis all may
have preceded the Koplik spots. The difficulty, therefore, of select-
ing a suitable time for the parenteral injection of large amounts of
immune bodies in the treatment of measles is very great. This
difficulty is well illustrated in Chart 1, which indicates the chrono-
logic order of appearance of the first signs and symptoms, the Kop-
lik spots and the rash, in a group of 44 children within a single
enclosed space, 43 of whom developed severe measles. (This
group of children was studied in conjunction with Dr. Elizabeth P.
Maris, who was chiefly responsible for their care.)
It will be noted that if the diagnosis of measles and therefore
the injection of immune bodies in large amounts for treatment had
depended upon the time of appearance of the Koplik spots, great
variations wo-uld necessarily have occurred in the interval between
the onset of fever and the time of treatment. Such a variation did
actually occur in a group of children injected intramuscularly, fol-
lowing the appearance of Koplik spots, with the gamma globulin
fraction II of pooled plasma, fractionated according to the method
of Cohn.t
* In measles, as in other diseases with long incubation periods, the use of immune
bodies during the early incubation stage has been termed prophylaxis, at least by
clinicians. This term should probably be limited to the use of antibodies before
incubation has occurred. It may be felt that the term treatment should not be used
unless one can be certain the virus is present in the individual. In reply to such a
premise it may be stated that the term prophylaxis as applied to injection of anti-
bodies after exposure, is ordinarily used with equal uncertainty as to whether or not
the virus is present. After exposure and during incubation, therefore, it would
appear to be accurate and less confusing to use the term treatment for the parenteral
injection of immune bodies, particularly in view of the findings herein described.
t More complete data concerning these children are to be published shortly by
Stokes, Maris, and Gellis.
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CHART 1
PROGRESS OF MEASLES EPIDEMIC IN A HOME FOR PRE-SCHOOL CHILDREN
PHILADELPHIA-1943
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In this group, treatment with large amounts of the globulin
containing approximately a 15- to 30-fold concentration of immune
bodies, as compared to pooled normal adult serum, was withheld
until Koplik spots appeared, but given prior to any rash. This
group of children had a striking modification of the disease as com-
pared with a group of cases first treated just after the rash had
appeared about the ears and face. The modification obtained in
the first group was most clearly evident in those children in whom
the Koplik spots appeared more than two days before the appearanceYALE JOURNAL OF BIOLOGY AND MEDICINE
of the rash. In such cases the rash was usually sparse, light in
color, and evanescent, and the cough and fever were greatly modi-
fied. On the other hand, CHART 2 modification of the disease
THERAPEUTIC USE OF GAMMA GLOBULIN
IN MEASLES, 1943 (61 CASES) by gamma globulin was not 17 so consistently obtained in
those children in whom
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ance of fever, conjunctivitis,
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and probably affords con-
clusive evidence of the value of such therapy.* Chart 2, from the
same group of cases, illustrates the difference between the value of
therapy before the rash appeared and after the earliest evidence
of rash.
The use of immune bodies in epidemic influenza
Little evidence is as yet available in human beings concerning
the use of immune bodies in the treatment of epidemic influenza
type A, while in influenza type B evidence concerning such therapy
is entirely lacking. In man the uncomplicated disease is usually
short-lived and specific therapy is extremely difficult to evaluate.
Smorodinzew and his co-workers8 have reported favorable results
from the use of homologous convalescent sera by inhalation in the
treatment of epidemic influenza type A in large groups of indi-
viduals. No confirmation of these findings has been obtained. In
mice, however, when they are injected intranasally under anesthesia
with dosages of influenza A and B viruses which ordinarily would
* Certain cases occur in which mild symptoms, including Koplik spots, are seen
without subsequent rash, but these do not appear to be of a florid type of measles
with severe cough and catarrhal signs.
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kill in four to six days, death may be prevented by the subsequent
intranasal or intraperitoneal injection of homologous immune sera.9
Such sera are more effective in the prevention of death when admin-
istered within 24 hours of the time of intranasal injection of virus,
but they may also be effective in influenza A virus even after 48
hours have elapsed from the time of infection and when the mouse
is obviously ill with severe influenza. It has been demonstrated
also' that the amount of serum required for such treatment and pro-
tection by the inhalation route is approximately one-tenth of the
amount required for similar results by the intraperitoneal route.
In the ferret, protection against the more severe complication of
pneumonia following intranasal infection could be obtained by simi-
lar inhalation of immune sera under anesthesia. It is also worth
indicating that in both mice and ferrets, similar injection of immune
sera by the respiratory route before infection of these animals with
influenza virus type A was highly effective in preventing the devel-
opment of the disease.
The use of immune bodies in poliomyelitis
Satisfactory experiments for the determination of the effect of
homologous antibodies in poliomyelitis have not been carried out
under natural conditions of infection and with recently isolated
strains of virus. Previous experiments conducted by Schultz and
his co-workers' have included the difficulties inherent in the use of a
virus (M. V. strain) long adapted to monkeys and injected intra-
cerebrally orbyintranasal instillation. Similardifficulties are inher-
ent in the use of the Lansing strain of virus injected intracerebrally
in mice and with a variable incubation period ranging in control mice
from approximately 4 to 14 days. Nevertheless, protection from
immune bodies injected intraperitoneally has been obtained in test
mice when the immune gamma globulin is thus injected in amounts
as small as 0.1 cc. at the time of intracerebral injection of the virus.*
A certain degree of protection is afforded 'by the same amount of
gamma globulin injected as long as 96 hours after intrmcerebral
injection of the virus. In these experiments the amount of virus
used was 0.1 per cent and the control mice were all dead from
poliomyelitis in 15 days. Kramer,5 in similar experiments in mice
with the Lansing strain of virus, has also obtained protection by
* This work has been carried out in conjunction with Dr. Werner Henle, Dr.
J. H. Jones, and Miss Claire Foster.YALE JOURNAL OF BIOLOGY AND MEDICINE
immune gamma globulin after the virus has been injected intra-
cerebrally.
Discussion
Over a period of years a small number of data similar to those
above outlined have accumulated which indicate that the use of
immune bodies for the treatment of specific diseases caused by intra-
cellular parasites should receive increasing attention.
(a) The use of immune bodies in measles differs from their
use in many other virus diseases primarily because of the different
group of cells parasitized and secondarily because of the long incuba-
tion period of the disease. Accurate knowledge of the development
of the virus of measles during its incubation phase and its spread
to the cells of the skin and mucous membrane has not been obtained,
but in general it may be said that the virus is multiplying in the
blood stream during the prodromal phases of the disease while the
Koplik spots and early rash are appearing. As the rash becomes
more pronounced, it apparently leaves the blood stream and is prob-
ably present almost entirely in the cells of the mucous membranes
and skin. What the activity of the virus may be during at least the
first seven days following the exposure of a susceptible is not known,
but at least the parenteral injection of homologous antibodies during
this phase of its development will either attenuate or prevent the
disease, depending upon the -amount used and upon other well-
known factors. From the time of exposure, the use of immune
bodies has been' considered by clinicians as prophylaxis until the
onset of fever, after which their use has been considered as treat-
ment. The lack of justification for such a division between pro-
phylaxis and treatment has already been indicated. The fact that
by means of immune bodies the rash may be limited after the fever
has started to a few lesions on the face and neck, or even prevented
from appearing, suggests that the virus is neutralized in transit
from one group of cells to another and by a protective action of
the circulating immune bodies surrounding the susceptible cells.
It would thus appear that future success in the treatment of measles
with immune bodies will depend to a great extent upon the devel-
opment of methods for earlier diagnosis of the disease. In most
instances the first appearance of Koplik spots will be a great aid
in such treatment, but in certain instances, as indicated previously,
their appearance is close to or almost co-incident with the rash.
Obviously also, a history of exposure would assist in the diagnosis.
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The fact that treatment in the children mentioned was more suc-
cessful when the rash appeared two to three days after the appear-
ance of Koplik spots may only indicate that the rash was delayed
by gamma globulin. However, this does not seem probable inas-
much as immune bodies injected soon after exposure do not appear
to lengthen the time between the appearance of the Koplik spots
and of the rash, even though they attenuate the disease.
(b) In attempts to investigate the value of immune bodies in
influenza by means of animal hosts, life or death must too frequently
be used as the criterion of success or failure of a therapeutic measure.
Particularly in small animals, fever and symptoms cannot be prop-
erly recorded and even in larger animals studies such as those
required for measles or epidemic influenza are usually hampered by
the lack of the secondarily invading bacteria so common and serious
in the human host. Thus one would not be justified in the con-
clusion that homologous immune serum is of little value in the
treatment of human influenza type A at the height of the disease
merely because of the fact that infected mice cannot be prevented
from dying if the immune serum is administered more than 48 hours
from the time of intranasal injection of the virus. On the other
hand, because the respiratory tract of the mouse is relatively small,
it is possible that impracticable amounts of homologous immune
sera would be required by inhalation in the human being for the
same favorable result as is obtained in the case of the infected mouse.
The respiratory tracts of the ferret or of the hog are more closely
analogous to that of the human being and here also secondarily
invading bacteria are more common, but unfortunately the practical
problems of the use of immune sera in such animals have not pro-
ceeded jointly with the studies of the causative agents of epidemic
influenza and their effects.
The adaptation of the intracellular parasite in influenza to its
new animal host or to the chick embryo and the resulting antigenic
changes in the parasite make it more difficult than is the case in bac-
terial pathogens to transfer the results of the use of immune bodies
from these hosts to the human host. That such antigenic changes
are greater in influenza virus type A than was at first supposed is
suggested by the more recent work of Burnet concerning the 0 and
D forms of virus.2 The differences in the synergistic activity with
bacteria of the human influenza virus type A and the swine influenza
virus as studied by Bang' suggest also that if immune bodies areYALE JOURNAL OF BIOLOGY AND MEDICINE
to be used in treatment, their antigenic source must be properly
analyzed.
Possibly in virus diseases other than influenza A, if a more
accurate knowledge of the mode of attack were available, a more
effective application of immune bodies could be obtained. The
virus enters the respiratory tract usually by the airborne route and
probably progresses along the epithelium from above downwards or
outwards from its point of impingement, denuding the epithelium
to the basement membrane. Resistance to the virus depends appar-
ently not so much upon the epithelial cells of the respiratory tract
as upon the antibody titer of the secretions or fluids which bathe
them and which in turn reflect the antibody titer of the blood
plasma.3 Circulating antibodies may not, therefore, be so important
as is the concentration of antibodies locally, and in this manner the
use of concentrated antibody preparations such as immune globulin
may be of great assistance. Also, the method of spread of the virus
locally suggests that only certain epithelial cells are parasitized first
and that the progress of the viruses from cell to cell may be checked
or completely stopped by immune bodies locally or parenterally
administered. A sufficient concentration of antibodies at the proper
point and sufficiently early in the course of the disease in human
beings may be difficult to obtain. Studies in which human volun-
teers are exposed to large amounts of virus by inhalation do not
duplicate field conditions. The virus under field conditions may
be more virulent but the exposure to it may be less intense than
under experimental conditions. Nevertheless, the favorable results
in animals justify further studies of the use of homologous immune
bodies, particularly for treatment in the larger animals and in human
beings under epidemic field conditions. Even moderate diminution
in the severity of the disease would appear to justify such studies.
(c) In poliomyelitis the need for additional data is even more
striking. In studies of passive immunization and particularly in
the studies of treatment with immune bodies, the lack of the proper
type and amount of immune bodies, the lack of suitable animals,
thevariability ofincubation period, the differences in strains ofvirus,
and the low incidence of human cases have all tended to prevent
the development of sufficiently critical experiments.
In the studies on mice mentioned previously, evidences of ill-
ness and paralysis in almost all instances occurred within approxi-
mately 24 hours of death, because no satisfactory method has been
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developed for determining early symptomatic or febrile evidence of
poliomyelitis in these animals. It is possible that the mouse, which
is protected by heterologous immune bodies when injected intra-
peritoneally 96 hours after the intracerebral injection of virus, is
symptomatically ill from the virus at or near the time of the intra-
peritoneal injection. Many of the infected mice when immune
bodies are not injected die within 4 to 8 days of the time of intra-
cerebral inoculation. Intracerebral inoculation of virus may be con-
sidered also as a severe test of the effectiveness of immune bodies.
In view of these considerations, further studies are indicated con-
cerning the early recognition of signs and symptoms of the disease
in the mouse as well as in the monkey and the development of a
method of inoculation of virus in such animals which would permit
a more constant incubation period and under conditions which would
resemble more closely those of natural infection.
From a general consideration of these three infectious diseases
as related to others caused by intracellular parasites, it is obvious that
the value of immune bodies varies with each agent of disease, its
site of attack, the incubation period, and a number of other factors.
It appears probable that upon the concentration or availability of the
immune bodies at the time the cells are selected for attack by the
parasite depends the success of such therapy. In poliomyelitis, for
example, the concentration of immune bodies at the site of attack
may be far less and thus less effective than for influenza in which
immune bodies may be concentrated in the secretions, the lymph,
and upon the surface by inhalation. In neither of these diseases,
however, are the limiting factors thoroughly understood.
In the rickettsial disease Rocky Mountain spotted fever, it has
been demonstrated that death can be prevented in infected guinea-
pigs if sufficient homologous antibodies are injected during the early
febrile period of the disease. Similar observations in human beings
appear to confirm these findings."0 As in measles, the value of
immune bodies is evident after the febrile onset of the disease has
occurred, but only if they are administered shortly after fever has
appeared.
From the foregoing findings, the conclusion may be drawn that
for each intracellular parasite the appropriate time should be deter-
mined experimentally beyond which the parenteral injection of anti-
bodies, even in large numbers, is no longer effective. It also may
be concluded that if large amounts of antibodies are effective in424 YALE JOURNAL OF BIOLOGY AND MEDICINE
modifying the disease when they are injected in its early stages,
they would be more effective in modifying or attenuating the dis-
ease if even earlier injection were made possible by earlier diagnosis.
Conclusions
The effective use of gamma globulin from large pools of normal
adult plasma in the attenuation of measles even when injected after
the onset of fever and the appearance of Koplik spots indicates the
need for the development of earlier diagnostic criteria for this dis-
ease and possibly for other diseases caused by intracellular parasites.
Data bearing on epidemic influenza type A in mice and ferrets and
on poliomyelitis in mice (Lansing strain) also emphasize the need
for additional studies in these diseases.
In view of the confusion in the terminology used by clinicians
and the need for earlier diagnostic criteria and treatment, it is sug-
gested that the term prophylaxis be limited to the use of immune
bodies previous to the exposure of the susceptible individual and
that their use following exposure and during incubation should be
termed treatment, whether or not one can demonstrate the presence
of the disease agent in the exposed susceptible at the time of
treatment.
It is anticipated that with the development of more concentrated
and effective homologous antibody preparations and earlier criteria
of disease, additional intracellular parasites will be brought under
more effective therapeutic control.
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